Trial Profile
A Phase II, Open-Label, Single-Arm Trial Using KEYTRUDA (Pembrolizumab) as Initial Systemic Therapy in the Treatment of Advanced Mycosis Fungoides
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- 01 Sep 2023 Planned primary completion date changed from 11 Oct 2023 to 11 Oct 2024.
- 01 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2023 Planned End Date changed from 11 Oct 2023 to 11 Oct 2024.